Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint
[at noodls] – sNDA Submission Expected in Second Quarter of 2014 with a 10-month PDUFA Timeline PARSIPPANY, N.J.–(BUSINESS WIRE)–Feb. 27, 2014– Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the … more
View todays social media effects on PCRX
View the latest stocks trending across Twitter. Click to view dashboard